Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with narcolepsy type 1 (NT1) - TAK-861-1012
Latest Information Update: 17 Dec 2025
At a glance
- Drugs Oveporexton (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Pharmacokinetics
- Sponsors Takeda
Most Recent Events
- 17 Dec 2025 New trial record